Metabolic modifications in human biofluids suggest the involvement of sphingolipid, antioxidant, and glutamate metabolism in alzheimer's disease pathogenesis

Journal of Alzheimer's Disease

Volumn 46, Issue 2, 2015, Pages 313-327

  Ellis, Ben ^a   Hye, Abdul ^a   Snowden, Stuart G ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antioxidant; glutamate; metabolism; metabolomics; neurodegeneration; sphingolipid

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; 8 HYDROXYGUANINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ASPARAGINE; CARNOSINE; CERAMIDE; DEHYDROASCORBIC ACID; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; INOSITOL; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; SUCCINIC ACID; URIC ACID; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ASTROCYTE; BLOOD ANALYSIS; BODY FLUID; CEREBROSPINAL FLUID ANALYSIS; DISEASE ASSOCIATION; EXCITOTOXICITY; HUMAN; LIPID BILAYER; LIPID PEROXIDATION; METABOLITE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALIVA ANALYSIS; SPHINGOLIPID METABOLISM; URINALYSIS; BRAIN; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; BRAIN; GLUTAMIC ACID; HUMANS; OXIDATIVE STRESS; SPHINGOLIPIDS;

EID: 84930443166     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141899     Document Type: Review

References (109)

1. Alzheimer's Association. What is dementia? http://www.alz.org/what-is-dementia.asp, Accessed 06-01
2. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7, 137-152
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191
4. Prince M, Prina M, Guerchet M (2013) World Alzheimer Report 2013, Alzheimer's Disease International, London.
5. Minati L, Edginton T, Bruzzone MG, Giaccone G (2009) CurrentconceptsinAlzheimer's disease: Amultidisciplinary review. Am J Alzheimers Dis Other Demen 24, 95-121
6. Turner PR, O'Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70, 1-32
7. El-Agnaf OMA, Mahil DS, Patel BP, Austen BM (2000) Oligomerization and toxicity of beta-Amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun 273, 1003-1007
8. Bennecib M, Gong C-X, Grundke-Iqbal I, Iqbal K (2000) Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 485, 87-93
9. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720-U725
10. Terry RD, Masliah E, Salmon DP, Butters N, Deteresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease -synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580
11. Armstrong RA, Myers D, Smith CUM (1993) The spatial patterns of plaques and tangles in Alzheimer's -disease do not support the cascade hypothesis. Dementia 4, 16-20
12. ReitzC(2012) Alzheimer's disease and the amyloid cascade hypothesis: A critical review. Int J Alzheimers Dis 2012, 369808-369808
13. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R (2011) Metabolomics in early Alzheimer's disease: Identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6, e21643
14. Trushina E, Dutta T, Persson X-MT, Mielke MM, Petersen RC (2013) Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One 8, e63644
15. Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, Doraiswamy PM, Welsh-BohmerKA(2011) Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement 7, 309-317
16. Kaddurah-Daouk R, Zhu H, Sharma S, BogdanovM, Rozen SG, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM, Arnold SE (2013) Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry 3, e244
17. Snowden S, Dahlen S-E, Wheelock CE (2012) Application of metabolomics approaches to the study of respiratory diseases. Bioanalysis 4, 2265-2290
18. Fiehn O (2002) Metabolomics -the link between genotypes and phenotypes. Plant Mol Biol 48, 155-171
19. Inoue K, Tsutsui H, Akatsu H, Hashizume Y, Matsukawa N, Yamamoto T, Toyo'oka T (2013) Metabolic profiling of Alzheimer's disease brains. Sci Rep 3, 2364
20. Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, Seppanan-Laakso T, Julkunen V, Gopalacharyulu PV, Hallikainen M, Koikkalainen J, Kivipelto M, Helisalmi S, Lotjonen J, Soininen H (2011) Metabolome in progression to Alzheimer's disease. Transl Psychiatry 1, e57
21. Czech C, Berndt P, Busch K, Schmitz O, Wiemer J, Most V, Hampel H, Kastler Jr, Senn H (2012) Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One 7, e31501
22. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C (2009) A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 30, 1235-1239
23. Ibanez C, Simo C, Martin-Alvarez PJ, Kivipelto M, Winblad B, Cedazo-Minguez A, Cifuentes A (2012) Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem 84, 8532-8540
24. Harada M, Taki M, Nose A, Kubo H, Mori K, Nishitani H, Matsuda T (2011) Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 Tesla instrument. J Autism Dev Disord 41, 447-454
25. Xu X-H, Huang Y, Wang G, Chen S-D (2012) Metabolomics: A novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease. Neurosci Bull 28, 641-648
26. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y (2012) Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res 53, 567-576
27. Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28, 27-30
28. Shetty HU, Holloway HW, Schapiro MB (1996) Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols inAlzheimer's disease. ClinChem42, 298-302
29. Ryberg H, Soderling AS, Davidsson P, Blennow K, Caidahl K, Persson LI (2004) Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer's disease. Neurochem Int 45, 57-62
30. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C (1999) Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 269, 52-54
31. Kester MI, Scheffer PG, Koel-Simmelink MJ, Twaalfhoven H, Verwey NA, Veerhuis R, Twisk JW, Bouwman FH, Blankenstein MA, Scheltens P, Teunissen C, van der Flier WM (2012) Serial CSF sampling in Alzheimer's disease: Specific versus non-specific markers. Neurobiol Aging 33, 1591-1598
32. Pomara N, Singh R, Deptula D, Chou JCY, Schwartz MB, Lewitt PA (1992) Glutamate and other CSF amino-Acids in Alzheimer's disease. Am J Psychiatry 149, 251-254
33. Kuiper MA, Teerlink T, Visser JJ, Bergmans PLM, Scheltens P, Wolters EC (2000) L-Glutamate, L-Arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 107, 183-189
34. Redjems-Bennani N, Jeandel C, Lefebvre E, Blain H, Vidailhet M, Gueant JL (1998) Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology 44, 300-304
35. Smith CCT, Bowen DM, Francis PT, Snowden JS, Neary D (1985) Putative amino-Acid transmitters in lumbar cerebrospinal-fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry 48, 469-471
36. D'Aniello A, Fisher G, Migliaccio N, Cammisa G, D'Aniello E, Spinelli P (2005) Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients. Neurosci Lett 388, 49-53
37. Spiegel S, Milstien S (2002) Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 277, 25851-25854
38. Spiegel S, Milstien S (1995) Sphingolipid metabolites: Members of a new class of lipid second messengers. J Membr Biol 146, 225-237
39. Ohanian J, Liu G, Ohanian V, Heagerty AM (1998) Lipid second messengers derived from glycerolipids and sphingolipids, and their role in smooth muscle function. Acta Physiol Scand 164, 533-548
40. Pralhada Rao R, Vaidyanathan N, Rengasamy M, Mammen OommenA, Somaiya N, JagannathMR(2013) Sphingolipid metabolic pathway: An overview of major roles played in human diseases. J Lipids 2013, 178910-178910
41. Lozano J, Berra E, Municio MM, Diaz-Meco MT, Dominguez I, Sanz L, Moscat J (1994) Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J Biol Chem 269, 19200-19202
42. Heinrich M, Wickel M, Schneider-Brachert W, Sandberg C, Gahr J, Schwandner R, Weber T, Brunner J, Krönke M, Schütze S (1999) Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J 18, 5252-5263
43. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA (1993) Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 268, 15523-15530
44. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM (2003) Ceramide stabilizes beta-site amyloid precursor proteincleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278, 19777-19783
45. Patil S, Melrose J, Chan C (2007) Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci 26, 2131-2141
46. Patil S, Sheng L, Masserang A, Chan C (2006) Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci Lett 406, 55-59
47. Malaplate-Armand C, Florent-Bechard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier JL, Oster T, Pillot T (2006) Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA(2)-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 23, 178-189
48. Jana A, Pahan K (2010) Fibrillar amyloid-Activated human astroglia kill primary human neurons via neutral sphingomyelinase: Implications for Alzheimer's disease. J Neurosci 30, 12676-12689
49. Yoshimura S-i, Banno Y, Nakashima S, Hayashi K, Yamakawa H, Sawada M, Sakai N, Nozawa Y (1999) Inhibition of neutral sphingomyelinase activation and ceramide formation by glutathione in hypoxic PC12 cell death. J Neurochem 73, 675-683
50. Dinkins MB, Dasgupta S, Wang G, Zhu G, Bieberich E (2014) Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 35, 1792-1800
51. He X, Huang Y, Li B, Gong C-X, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31, 398-408
52. Ledesma MD, Correas I, Avila J, Diaz-Nido J (1992) Implication of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer's disease. FEBS Lett 308, 218-224
53. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10, 279-288
54. Shen C, Chen Y, Liu H, Zhang K, Zhang T, Lin A, Jing N (2008) Hydrogen peroxide promotes A beta production through JNK-dependent activation of gamma-secretase. J Biol Chem 283, 17721-17730
55. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449
56. ZhaoY, ZhaoB(2013) Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Long 2013, 316523-316523
57. Monaco Iii EA (2004) Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease. Curr Alzheimer Res 1, 33-38
58. Bu B, Li J, Davies P, Vincent I (2002) Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick Type C murine model. J Neurosci 22, 6515-6525
59. Cruz JC, Tseng H-C, Goldman JA, Shih H, Tsai L-H (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483
60. Zheng Y-L, Kesavapany S, Gravell M, Hamilton RS, Schubert M, Amin N, Albers W, Grant P, Pant HC (2005) A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J 24, 209-220
61. Butterfield DA, Hensley K, Harris M, Mattson M, Carney J (1994) -Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: Implications to Alzheimer's disease. Biochem Biophys Res Commun 200, 710-715
62. Butterfield DA, Swomley AM, Sultana R (2013) Amyloid -peptide (1-42)-induced oxidative stress in Alzheimer disease: Importance in disease pathogenesis and progression. Antioxid Redox Signal 19, 823-835
63. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA (1994) A model for beta-Amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci U S A 91, 3270-3274
64. Li F, Calingasan NY, Yu FM, Mauck WM, Toidze M, Almeida CG, Takahashi RH, Carlson GA, BealMF, LinMT, GourasGK(2004) Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 89, 1308-1312
65. Nishida Y, Yokota T, Takahashi T, Uchihara T, Jishage K-i, Mizusawa H (2006) Deletion of vitamin E enhances phenotype of Alzheimer disease model mouse. Biochem Biophys Res Commun 350, 530-536
66. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (2014) Effect of vitamin e and memantine on functional decline in Alzheimer disease: The team-Ad va cooperative randomized trial. JAMA 311, 33-44
67. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336, 1216-1222
68. Lloret A, Badía M-C, Mora NJ, Pallardó FV, Alonso M-D, Viña J (2009) Vitamin E paradox in Alzheimer's disease: It does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 17, 143-149
69. Selley ML, Close DR, Stern SE (2002) The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 23, 383-388
70. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid -peptide. J Neurochem 68, 255-264
71. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP (1997) Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid -peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 69, 273-284
72. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of A-1-42. J Neurochem 78, 413-416
73. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408, 239-247
74. Sohal RS, Weindruch R (1996) Oxidative stress, caloric restriction, and aging. Science 273, 59-63
75. ButterfieldDA, ReedT, NewmanFS, SultanaR(2007) Roles of amyloid -peptide-Associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43, 658-677
76. Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: Review of physiology and pathology. J Nutr 130, 1007
77. Abe T, Sugihara H, Nawa H, Shigemoto R, Mizuno N, Nakanishi S (1992) Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+signal transduction. J Biol Chem 267, 13361-13368
78. Coggeshall RE, Carlton SM (1998) Ultrastructural analysis of NMDA, AMPA, and kainate receptors on unmyelinated and myelinated axons in the periphery. J Comp Neurol 391, 78-86
79. Anderson CM, Swanson RA (2000) Astrocyte glutamate transport: Review of properties, regulation, and physiological functions. Glia 32, 1-14
80. Platt SR (2007) The role of glutamate in central nervous system health and disease -A review. Vet J 173, 278-286
81. Rousseaux CG (2008) A review of glutamate receptors II: Pathophysiology and pathology. J Toxicol Pathol 21, 133-173
82. Rousseaux CG (2008) A review of glutamate receptors I: Current understanding of their biology. J Toxicol Pathol 21, 25-51
83. DanyszW, Parsons CG (2003) TheNMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: Preclinical evidence. Int J Geriatr Psychiatry 18, S23-S32
84. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45, 583-595
85. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB (1988) Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 12, 421-430
86. Butterfield DA, Pocernich CB (2003) The glutamatergic system and Alzheimer's disease -Therapeutic implications. CNS Drugs 17, 641-652
87. Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, Bummer PM, Haley BE, Carney JM (1997) Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: Relevance to Alzheimer's disease. J Neurochem 68, 2451-2457
88. Aksenov MY, Aksenova MV, Carney JM, Buterfield DA (1997) Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Radical Res 27, 267-281
89. Aksenov MY, Aksenova MV, Harris ME, Hensley K, Butterfield DA, Carney JM (1995) Enhancement of -Amyloid peptide A-(1-40)-mediated neurotoxicity by glutamine synthetase. J Neurochem 65, 1899-1902
90. Procter AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, Doshi R, Bowen DM (1988) Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem 50, 790-802
91. Hege Nilsen L, Rae C, Ittner LM, Gotz J, Sonnewald U (2013) Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab 33, 684-691
92. Cassano T, Serviddio G, Gaetani S, Romano A, Dipasquale P, Cianci S, Bellanti F, Laconca L, Romano AD, Padalino I, LaFerla FM, Nicoletti F, Cuomo V, Vendemiale G (2012) Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging 33, 1121.e1-12
93. Gordon-Krajcer W, Salinska E, Lazarewicz JW (2002) N-methyl-d-Aspartate receptor-mediated processing of betaamyloid precursor protein in rat hippocampal slices: in vitro -superfusion study. Folia Neuropathol 40, 13-17
94. McKeage K (2009) Memantine: A review of its use in moderate to severe Alzheimer's disease.CNSDrugs 23, 881-897
95. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study, Group (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341
96. Winblad B, Poritis N (1999) Memantine in severe dementia: Results of the M-9-BEST study (benefit and efficacy in severly demented patients during treatment with memantine). Int J Geriatr Psychiatry 14, 135-146
97. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G (2002) Neuroprotection by memantine against neurodegeneration induced by beta-Amyloid(1-40). Brain Res 958, 210-221
98. Ferrarese C, Pecora N, Frigo M, Appollobnio I, Frattola L (1993) Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid. Ann Neurol 33, 316-319
99. Sumner L, Amberg A, Barrett D, Beale M, Beger R, Daykin C, Fan TM, Fiehn O, Goodacre R, Griffin J, Hankemeier T, Hardy N, Harnly J, Higashi R, Kopka J, Lane A, Lindon J, Marriott P, Nicholls A, Reily M, Thaden J, Viant M (2007) Proposed minimum reporting standards for chemical analysis. Metabolomics 3, 211-221
100. Gottesman II (2003) The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry 160, 636-645
101. Satoi H, Tomimoto H, Ohtani R, Kitano T, Kondo T, Watanabe M, Oka N, Akiguchi I, Furuya S, HirabayashiY, Okazaki T (2005) Astroglial expression of ceramide in Alzheimer's disease brains: A role during neuronal apoptosis. Neuroscience 130, 657-666
102. Kosicek M, Kirsch S, Bene R, Trkanjec Z, Titlic M, Bindila L, Peter-Katalinic J, Hecimovic S (2010) Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer's disease patients-A pilot study. Anal Bioanal Chem 398, 2929-2937
103. Ibanez C, Simo C, Barupal DK, Fiehn O, Kivipelto M, Cedazo-Monguez A, Cifuentes A (2013) A new metabolomic workflow for early detection of Alzheimer's disease. J Chromatogr A 1302, 65-71
104. Lovell MA, Markesbery WR (2001) Ratio of 8-hydroxyguanine in intact dna to free 8-hydroxyguanine is increased in alzheimer disease ventricular cerebrospinal fluid. Arch Neurol 58, 392-396
105. Abe T, Tohgi H, Isobe C, Murata T, Sato C (2002) Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res 70, 447-450
106. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, Regland Bj (2003) Alzheimer's disease and total plasma aminothiols. Biol Psychiatry 53, 254-260
107. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG (2007) Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids 32, 213-224
108. Basun H, Forssell LG, Almkvist O, Cowburn RF, Eklaf R, Winblad B, Wetterberg L (1990) Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer's disease and healthy control subjects. J Neural Transm Park Dis Dement Sect 2, 295-304
109. Degrell I, Hellsing K, Nagy E, Niklasson F (1989) Amino acid concentrations in cerebrospinal fluid in presenile and senile dementia of Alzheimer type and multi-infarct dementia. Arch Gerontol Geriatr 9, 123-135